Novel Small Molecule GLP-1R Agonists Based on 1H-Benzo[d]imidazole-5-Carboxylic Acid Scaffold
Molecules · 29.03.2026 · 31 (7) · 1129
DOI: 10.3390/molecules31071129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 29.03.2026. Verfasst von Elena V Tolkacheva und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Biotechnology Department, Sirius University of Science and Technology, Olimpiyskiy Ave. 1, Sirius 354340, Krasnodar Region, Russia. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Benzimidazoles, Hypoglycemic Agents. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation.
Abstract (Originalsprache)
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by intestinal endocrine L cells that activates the GLP-1 receptor (GLP-1R), leading to glucose-dependent insulin secretion and suppression of glucagon release. In recent years, GLP-1R agonists (GLP-1RAs) have become one of the leading therapeutic options for the treatment of type 2 diabetes mellitus; however, for a long time clinically approved GLP-1RAs were limited to peptide drugs unsuitable for oral administration. The discovery of the “first-in-class” small molecule agonist danuglipron in 2018 demonstrated the feasibility of orally available GLP-1RAs and stimulated the development of numerous danuglipron-like compounds, some of which showed increased efficacy over the prototype. In this study, we report the design and synthesis of novel GLP-1RAs based on a regioisomeric danuglipron scaffold, 1H-benzo[d]imidazole-5-carboxylic acid. A series of 35 compounds was synthesized and evaluated in vitro for cytotoxicity and GLP-1R agonistic activity using a cAMP accumulation assay. A potent lead compound 12r (pEC50 = 7.72, pCC50 < 3.60) was found which is a close structural analog of danuglipron with reduced cytotoxicity and excellent selectivity over two other class B GPCRs, including GCGR and GIPR. Despite decreased potency compared to danuglipron, the obtained results hold promise for further optimization and provide valuable structure–activity relationship insights.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicinal Biotechnology Department, Sirius University of Science and Technology, Olimpiyskiy Ave. 1, Sirius 354340, Krasnodar Region, Russia.
- Laboratory of Structural Dynamics, Stability and Folding of Proteins, Institute of Cytology, Russian Academy of Sciences, Tikhoretsky Ave. 4, St. Petersburg 194064, Russia.
- Institute of Future Biophysics, Institutsky Lane, 9, Dolgoprudny 141700, Moscow Region, Russia.
ORCID-Profile: Elena V Tolkacheva, Alexandr Yu Saliev, Eugene Y Smirnov, Sergey A Silonov, Konstantin V Balakin, Vladimir V Chernyshov, Roman A Ivanov
Förderung
- Ministry of Science and Higher Education of the Russian Federation
Zitieren
APA
Tolkacheva, E. V., Salakhov, T. L., Saliev, A. Y., Lebedeva, N. D., Krasnodubets, A. M., Smirnov, E. Y., Silonov, S. A., Balakin, K. V., Chernyshov, V. V., & Ivanov, R. A. (2026). Novel Small Molecule GLP-1R Agonists Based on 1H-Benzo[d]imidazole-5-Carboxylic Acid Scaffold. Molecules, 31(7), 1129. https://doi.org/10.3390/molecules31071129
Vancouver
Tolkacheva EV, Salakhov TL, Saliev AY, Lebedeva ND, Krasnodubets AM, Smirnov EY, et al. Novel Small Molecule GLP-1R Agonists Based on 1H-Benzo[d]imidazole-5-Carboxylic Acid Scaffold. Molecules. 2026;31(7):1129. doi:10.3390/molecules31071129
BibTeX
@article{Tolkacheva2026,
author = {Tolkacheva, Elena V and Salakhov, Tagir L and Saliev, Alexandr Yu and Lebedeva, Natalia D and Krasnodubets, Alisa M and Smirnov, Eugene Y and Silonov, Sergey A and Balakin, Konstantin V and Chernyshov, Vladimir V and Ivanov, Roman A},
title = {Novel Small Molecule GLP-1R Agonists Based on 1H-Benzo[d]imidazole-5-Carboxylic Acid Scaffold},
journal = {Molecules},
year = {2026},
volume = {31},
number = {7},
pages = {1129},
doi = {10.3390/molecules31071129}
}
EUVIMED